Show simple item record

dc.contributor.authorConibear, J
dc.contributor.authorChia, B
dc.contributor.authorNgai, Y
dc.contributor.authorBates, A
dc.contributor.authorCounsell, N
dc.contributor.authorPatel, R
dc.contributor.authorEaton, D
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorFenwick, J
dc.contributor.authorForster, M
dc.contributor.authorHanna, G
dc.contributor.authorHarden, S
dc.contributor.authorMayles, P
dc.contributor.authorMoinuddin, S
dc.contributor.authorLandau, D
dc.date.accessioned2018-06-27T20:11:38Z
dc.date.available2018-06-27T20:11:38Z
dc.date.issued2018-04-17
dc.identifier.citationStudy protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. 2018, 8(4): BMJ Openen
dc.identifier.issn2044-6055
dc.identifier.pmid29666135
dc.identifier.doi10.1136/bmjopen-2017-020690
dc.identifier.urihttp://hdl.handle.net/10541/621061
dc.description.abstractFollowing growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS.
dc.language.isoenen
dc.rightsArchived with thanks to BMJ openen
dc.titleStudy protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentSt Bartholomew's Hospital, London, UKen
dc.identifier.journalBMJ Openen
refterms.dateFOA2018-12-17T15:26:53Z
html.description.abstractFollowing growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS.


Files in this item

Thumbnail
Name:
e020690.full.pdf
Size:
1.330Mb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record